Skip to main content
Springer Nature Link
Log in

Selection of Drugs for Intraperitoneal Chemotherapy for Ovarian Cancer

  • Chapter
  • First Online:
Intraperitoneal Therapy for Ovarian Cancer

  • 436 Accesses

Abstract

Intraperitoneal therapy improves the survival of women with ovarian cancer that has been extensively removed at primary surgery. This chapter reviews the basic pharmacologic principles that underlie the use of intraperitoneal therapy and highlights the key factors that determine the pharmacologic advantage of this route of administration. Limited penetration of drug from the surface of tumor nodules is a major challenge. Important determinants of penetration include drug concentration gradients, blood flow in the tumor nodule, capillary permeability, and the ability of the drug to bind to extracellular components of the tumor. Pharmacologic strategies for manipulating these factors promise further improvement in the efficacy and safety of intraperitoneal chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Trimble EL, Christian MC (2006) Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 100:3–4

    Article  PubMed  Google Scholar 

  2. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11

    PubMed  CAS  Google Scholar 

  3. Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89:480–487

    Article  PubMed  CAS  Google Scholar 

  4. Howell SB, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, Weiss RJ (1987) Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607–1612

    PubMed  CAS  Google Scholar 

  5. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389–394

    Article  PubMed  CAS  Google Scholar 

  6. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851

    PubMed  CAS  Google Scholar 

  7. Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, Cates C, Howell SB (1994) A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 54:338–344

    Article  PubMed  CAS  Google Scholar 

  8. Elferink F, Vander Vijgh WJF, Klein I, Ten Bokkel Huinink WW, Dubbleman R, McVie JG (1988) Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol 21:4157–4160

    Article  Google Scholar 

  9. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426–1431

    PubMed  CAS  Google Scholar 

  10. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, Hurowitz L, Almadrones L, Hoskins W (1992) Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J Clin Oncol 10:1485–1491

    PubMed  CAS  Google Scholar 

  11. Los G, Verdegaal EM, Mutsaers PH, McVie JG (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28:159–165

    Article  PubMed  CAS  Google Scholar 

  12. Jandial DD, Farshchi-Heydari S, Pu M, Messer K, Howell SB (2009) Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model. Gynecol Oncol 115:362–6. PMID: 19775736; PMCID: PMC2707998

    Article  PubMed  CAS  Google Scholar 

  13. Howell SB, Chu BB, Wung WE, Metha BM, Mendelsohn J (1981) Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161–1170

    Article  PubMed  CAS  Google Scholar 

  14. Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244:106–112

    Article  PubMed  Google Scholar 

  15. Favoulet P, Magnin G, Guilland JC, Beltramo JL, Osmak L, Benoit L, Rat P, Douvier S, Duvillard C, Chauffert B (2001) Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis. Eur J Surg Oncol 27:59–64

    Article  PubMed  CAS  Google Scholar 

  16. Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B (2006) Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 17:1211–1217

    Article  PubMed  CAS  Google Scholar 

  17. Shah DK, Shin BS, Veith J, Toth K, Bernacki RJ, Balthasar JP (2009) Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 329:580–591

    Article  PubMed  CAS  Google Scholar 

  18. Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902–2908

    Article  PubMed  CAS  Google Scholar 

  19. King ME, Pfeifle CE, Howell SB (1984) Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 2:662–669

    PubMed  CAS  Google Scholar 

  20. Kirmani S, Zimm S, Cleary SM, Mowry J, Howell SB (1990) Extremely prolonged continuous intraperitoneal infusion of cytosine arabinoside. Cancer Chemother Pharmacol 25:454–458

    Article  PubMed  CAS  Google Scholar 

  21. Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, Safra T, Morrow CP (1997) Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin). Gynecol Oncol 66:290–294

    Article  PubMed  CAS  Google Scholar 

  22. Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S, Doroshow JH (2007) Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 13:1232–1237

    Article  PubMed  CAS  Google Scholar 

  23. Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O’Flaherty C, Bloss J, Chi D, Spriggs D (2004) Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 10:2962–2967

    Article  PubMed  CAS  Google Scholar 

  24. Armstrong DK, Fleming GF, Markman M, Bailey HH (2006) A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 103:391–396

    Article  PubMed  CAS  Google Scholar 

  25. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL (2007) Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res 24:1691–1701

    Article  PubMed  CAS  Google Scholar 

  26. Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M (2007) Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol 60:907–914

    Article  PubMed  CAS  Google Scholar 

  27. Xu P, Van Kirk EA, Murdoch WJ, Zhan Y, Isaak DD, Radosz M, Shen Y (2006) Anticancer efficacies of cisplatin-releasing pH-responsive nanoparticles. Biomacromolecules 7:829–835

    Article  PubMed  CAS  Google Scholar 

  28. Carlson CB, Mowery P, Owen RM, Dykhuizen EC, Kiessling LL (2007) Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem Biol 2:119–127

    Article  PubMed  CAS  Google Scholar 

  29. Dijkgraaf I, Kruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp RM, Boerman OC (2007) Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 120:605–610

    Article  PubMed  CAS  Google Scholar 

  30. Holzer AK, Katano K, Klomp LW, Howell SB (2004) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744–6749

    Article  PubMed  CAS  Google Scholar 

  31. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817–823

    Article  PubMed  CAS  Google Scholar 

  32. Larson CA, Blair BG, Safaei R, Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324–330

    Article  PubMed  CAS  Google Scholar 

  33. Holzer AK, Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944–10952

    Article  PubMed  CAS  Google Scholar 

  34. Jandial DD, Farshchi-Heydari S, Larson CA, Elliot GI, Wrasidlo WJ, Howell SB (2009) Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553–560

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and the Moores Cancer Center, University of California, 3855 Health Sciences Drive, La Jolla, CA, 92093-0819, USA

    Stephen B. Howell

Authors
  1. Stephen B. Howell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen B. Howell .

Editor information

Editors and Affiliations

  1. College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA

    David S. Alberts

  2. Arizona Cancer Center, University of Arizona, N. Campbell Ave. 1515, Tucson, 85724-5024, Arizona, USA

    Mary C. Clouser

  3. School of Medicine, Deps of Pub. Health and Obstetrics and G, Indiana University, N. Senate Ave. EF250 714, Indianapolis, IN, 46202, Arizona, USA

    Lisa M. Hess

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Howell, S.B. (2010). Selection of Drugs for Intraperitoneal Chemotherapy for Ovarian Cancer. In: Alberts, D., Clouser, M., Hess, L. (eds) Intraperitoneal Therapy for Ovarian Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12130-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12130-2_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12129-6

  • Online ISBN: 978-3-642-12130-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics